Table 1. Clinical features and responses of the case series analysed (208 patients).
| Features | No. (%) |
|---|---|
| Age (median) | 57.7 |
| Sokal risk Low Intermediate High |
100 (48.1%) 83 (39.9%) 25 (12%) |
| Type of transcript e13a2 e14a2 Both |
97 (46.6%) 108 (51.9%) 3 (1.4%) |
| Eutos risk Low High |
114 (54.8%) 94 (45.2%) |
| Cumulative incidence of CCyR (at 1 year) | 83% |
| Cumulative incidence of MR3 (at 7 years) | 70% |
| Cumulative incidence of MR4 (at 7 years) | 51.5% |
| Cumulative incidence of MR4.5 (at 7 years) | 48% |
| Primary resistance | 12% |
| Secondary resistance | 13% |
| BC progression | 3% |
| OS | 81.5% |
| EFS | 65% |